Overcoming drug resistance in patients with metastatic breast cancer

Pharmacotherapy

Volumn 29, Issue 8, 2009, Pages 954-965

  Wong, Serena T ^a   Goodin, Susan ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cytotoxic agents; Epothilones; Lapatinib; Metastatic breast cancer; Resistance; Taxanes

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTARABINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GLYCOPROTEIN P INHIBITOR; IRINOTECAN; IXABEPILONE; LAPATINIB; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CHEMOSENSITIVITY; CLINICAL TRIAL; CYTOTOXICITY; DISEASE FREE SURVIVAL; DNA DAMAGE; DNA REPAIR; DRUG ACTIVATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG INACTIVATION; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; HORMONAL THERAPY; HUMAN; METASTASIS; OVERALL SURVIVAL; REVIEW; SALVAGE THERAPY; SOLID TUMOR; TRANSACTIVATION; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MODELS, BIOLOGICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM METASTASIS;

EID: 68149169839     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.8.954     Document Type: Review

References (75)

1. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005;205:275-292
2. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008;26:44-53.
3. Conlin AK, Seidman AD. Taxanes in breast cancer: an update. Curr Oncol Rep 2007;9:22-30.
4. Gibson LJ, Dawson CK, Lawrence DH, Bliss JM. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2007;1:CD003370.
5. Jones SE. Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 2008;8:224-233 (Pubitemid 351962143)
6. Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 2006;11:325-335
7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792 (Pubitemid 32222155)
8. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008;26:2813-2820
9. Callaghan R, Ford RC, Kerr ID. The translocation mechanism of P-glycoprotein. FEBS Lett 2006;580:1056-1063
10. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008;34:378-390
11. Schwartz PM, Moir RD, Hyde CM, Turek PJ, Handschumacher RE. Role of uridine phosphorylase in the anabolism of 5-fluorouracil. Biochem Pharmacol 1985;34:3585-3589
12. Johnston PG, Drake JC, Trepel J, Allegra CJ. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992;52:4306-4312
13. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989;7:890-899 (Pubitemid 19172462)
14. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1-6. (Pubitemid 28062870)
15. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-4886 (Pubitemid 26374423)
16. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6. (Pubitemid 24054605)
17. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997;89:917-931 (Pubitemid 27282064)
18. Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994;54:5902-5910 (Pubitemid 24375226)
19. Honda J, Sassa M, Moriya T, et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer: preliminary results. J Med Invest 2008;55:54-60. (Pubitemid 351643594)
20. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-237
21. Yu Z, Yang Q, Sun J, Zhen J. Dihydropyrimidine dehydrogenase activity correlates with fluorouracil sensitivity in breast cancer. Exp Oncol 2007;29:192-196 (Pubitemid 350206745)
22. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-265
23. Desai A, Mitchison TJ. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 1997;13:83-117.
24. Sève P, Dumontet C. Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008;9:168-175
25. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-17125 (Pubitemid 27289821)
26. Burkhart CA, Kavallaris M, Band HS. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001;1471:O1-9. (Pubitemid 32146550)
27. Zhang CC, Yang JM, White E, Murphy M, Levine A, Hait WN. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 1998;16:1617-1624 (Pubitemid 28159910)
28. Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 2005;102:8315-8320 (Pubitemid 40800086)
29. Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bisaceto- ammine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999;59:3968-3971 (Pubitemid 29393563)
30. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331
31. Dart DA, Picksley SM, Cooper PA, Double JA, Bibby MC. The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment. Int J Oncol 2004;24:115-125
32. Aas T, Borresen AL, Geisler S, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-814 (Pubitemid 26225099)
33. Schmidt M, Bachhuber A, Victor A, et al. p53 expression and resistance against paclitaxel in patients with metastatic breast cancer. J Cancer Res Clin Oncol 2003;129:295-302. (Pubitemid 36791685)
34. Olopade OI, Adeyanju MO, Safa AR, et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am 1997;3:230-237 (Pubitemid 27327384)
35. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10(1 pt 2):S331-6. (Pubitemid 38116639)
36. Levin ER, Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 2008;108:351-361
37. Massarweh S, Osborne CK, Creighton CJ, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008;68:826-833 (Pubitemid 351206760)
38. Arpino G, Gutierrez C, Weiss H, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007;99:694-705. (Pubitemid 47073531)
39. Rimawi MF, Weiss HL, Arpino G, et al. Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu over-expressing breast tumor xenografts [abstract]. Breast Cancer Res Treat 2006;100(suppl 1):302.
40. Mackey JR, Kaufman B, Clemens M, et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer [abstract]. Breast Cancer Res Treat 2006;100(suppl 1):3.
41. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-9318
42. Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008;456:663-666 (Erratum in Nature 2009;457:1168.)
43. Rau KM, Kang HY, Cha TL, Miller SA, Hung MC. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer 2005;12:511-532
44. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167
45. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-365
46. Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65:473-482
47. Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGFI- induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004;108:334-341 (Pubitemid 37549597)
48. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004;64:3981-3986
49. Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002;62:3151-3158
50. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-137
51. Valabrega G, Montemurro F, Sarotto I, et al. TGFalpha expression impairs trastuzumab-induced HER2 downregulation. Oncogene 2005;24:3002-3010 (Pubitemid 40675531)
52. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-4141 (Pubitemid 34791085)
53. Chan CT, Metz MZ, Kane SE. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat 2005;91:187-201.
54. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-127 (Pubitemid 39485684)
55. Mavroudis D, Alexopoulos A, Malamos N, et al. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin: a multicenter phase II trial. Oncology 2003;64:207-212 (Pubitemid 36438804)
56. Perez EA, Hillman DW, Stella PJ, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000;88:124-131 (Pubitemid 30027687)
57. Laufman LR, Spiridonidis CH, Pritchard J, et al. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial. Ann Oncol 2001;12:1259-1264 (Pubitemid 32994754)
58. Jones D, Ghersi D, Wilcken N. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database Syst Rev 2006;3:CD003368.
59. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001;61(suppl 2):14-21. (Pubitemid 33033420)
60. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676
61. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799 (Pubitemid 46224178)
62. Stathopoulos GP, Tsavdaridis D, Malamos NA, et al. Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer Chemother Pharmacol 2005;56:487-491 (Pubitemid 41549150)
63. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-2025 (Pubitemid 41095195)
64. Lee JJ, Swain SM. The epothilones: translating from the laboratory to the clinic. Clin Cancer Res 2008;14:1618-1624
65. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-3406 (Pubitemid 47310875)
66. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-3414 (Pubitemid 47310876)
67. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-5217 (Pubitemid 350232252)
68. Hortobagyi GN, Perez E, Vrdoljak E, et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trials [abstract 186]. Presented at the 2008 American Society of Clinical Oncology Breast Cancer Symposium, Washington, DC, September 5-7, 2008.
69. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-1639 (Pubitemid 43259947)
70. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007;6:667-674 (Pubitemid 46332467)
71. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-543
72. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743 (Pubitemid 46021510)
73. Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 2006;103:7795-7800 (Pubitemid 43752860)
74. Pusztai L, Wagner P, Ibrahim N, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005;104:682-691 (Pubitemid 41114904)
75. Chi KC, Wallis AE, Lee CH, et al. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res Treat 2000;63:199-212.